We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+52.1%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.24B
AUM Growth
+$511M
Cap. Flow
-$50.3M
Cap. Flow %
-2.25%
Top 10 Hldgs %
66.48%
Holding
69
New
5
Increased
9
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$92.4M
2
ALGS icon
Aligos Therapeutics
ALGS
+$69.1M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$58.1M
4
TXG icon
10x Genomics
TXG
+$8.56M
5
ZLAB icon
Zai Lab
ZLAB
+$5.38M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$32.1M
2
ARWR icon
Arrowhead Research
ARWR
+$23.8M
3
SAGE
Sage Therapeutics
SAGE
+$21.6M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$21.6M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.89%
2 Financials 5.49%
3 Materials 3.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$20.1M 0.9%
1,006,494
+188,559
+23% +$3.85M
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.1M 0.85%
1,206,266
+182,554
+18% +$2.75M
NVAX icon
28
Novavax
NVAX
$1.27B
$17.6M 0.78%
157,487
-6,712
-4% -$713K
KURA icon
29
Kura Oncology
KURA
$817M
$17.2M 0.77%
525,262
-524,738
-50% -$18.4M
LRMR icon
30
Larimar Therapeutics
LRMR
$426M
$17.1M 0.76%
799,662
– –
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$382M
$17M 0.76%
310,584
-550,064
-64% -$20.1M
AKRO
32
DELISTED
Akero Therapeutics
AKRO
$16.3M 0.73%
633,426
+61,593
+11% +$1.71M
IMVT icon
33
Immunovant
IMVT
$8.06B
$16.1M 0.72%
347,662
-694,798
-67% -$32.1M
ARWR icon
34
Arrowhead Research
ARWR
$12.2B
$15.7M 0.7%
205,091
-371,414
-64% -$23.8M
MREO
35
Mereo BioPharma
MREO
$48.4M
$15.1M 0.67%
4,220,938
-2,000,000
-32% -$5.01M
CYTK icon
36
Cytokinetics
CYTK
$10.7B
$14.5M 0.65%
700,000
– –
ZYME icon
37
Zymeworks
ZYME
$1.73B
$13.5M 0.6%
286,064
-354,347
-55% -$16.5M
CRIS icon
38
Curis
CRIS
$8.85M
$11.5M 0.51%
+3,500
New +$4.2M
ACRS icon
39
Aclaris Therapeutics
ACRS
$888M
$10.7M 0.48%
1,647,214
– –
CALT
40
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$10.5M 0.47%
311,030
-268,970
-46% -$8.19M
PSTX
41
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.2M 0.45%
926,447
-2
-0% -$21
QTTB icon
42
Q32 Bio
QTTB
$490M
$9.63M 0.43%
47,397
– –
MTNB icon
43
Matinas BioPharma
MTNB
$1.76M
$8.77M 0.39%
129,032
-96,554
-43% -$4.47M
CDXS icon
44
Codexis
CDXS
$156M
$8.47M 0.38%
388,144
-1,088,145
-74% -$17.9M
TXG icon
45
10x Genomics
TXG
$6.03B
$8.35M 0.37%
+58,977
New +$8.56M
AUPH icon
46
Aurinia Pharmaceuticals
AUPH
$1.95B
$6.92M 0.31%
500,732
– –
DYN icon
47
Dyne Therapeutics
DYN
$4.89B
$6.62M 0.3%
315,000
– –
ORTX
48
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.73M 0.26%
132,574
– –
KALA icon
49
KALA BIO
KALA
$13.6M
$5.33M 0.24%
315
– –
CNST
50
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.04M 0.18%
140,298
– –
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.06% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return

Vivo Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Vivo Capital held 69 positions worth $2.24B, up 30% from $1.73B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Vivo Capital's Q4 2020 filing shows 5 new, 9 increased, 19 reduced and 10 closed positions. Its largest new stake was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M. The largest sale was Immunovant, an estimated $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q4 2020 buy was Tarsus Pharmaceuticals: 3,245,035 shares worth $134M.
  • Vivo Capital added most to Zai Lab in Q4 2020, an estimated $5.38M increase.
  • Vivo Capital's biggest Q4 2020 reduction was Immunovant, cutting an estimated $32.1M.
  • Vivo Capital fully exited Sage Therapeutics in Q4 2020, selling an estimated $21.6M.
  • Vivo Capital's ten largest holdings make up 66% of its $2.24B portfolio in Q4 2020.
  • Vivo Capital opened 5 new positions and closed 10 in Q4 2020.
  • Vivo Capital's portfolio value rose 30% quarter-over-quarter to $2.24B.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.